Results 121 to 130 of about 2,193 (158)
Enhanced In Vitro Stability of Bedaquiline with Ascorbic Acid and Pyruvate During Long-Term Incubation in <i>Mycobacterium</i> Species. [PDF]
Antibiotics (Basel)Batista S +8 more
europepmc +1 more source
Delamanid or pretomanid? A Solomonic judgement! [PDF]
Journal of Antimicrobial Chemotherapy, 2022 Abstract Given the low treatment success rates of drug-resistant tuberculosis (TB), novel TB drugs are urgently needed. The landscape of TB treatment has changed considerably over the last decade with the approval of three new compounds: bedaquiline, delamanid and pretomanid. Of these, delamanid and pretomanid belong to the same class of
Saskia E Mudde +2 more
exaly +3 more sources
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice
International Journal of Antimicrobial Agents, 2023 Pretomanid (PA-824), a novel anti-tuberculosis (TB) nitroimidazoxazine, has been approved for multi-drug-resistant TB treatment for a few years. Pretomanid has been demonstrated to be highly active against Mycobacterium tuberculosis when combined with other anti-TB drugs.
Thi Van Anh Nguyen +2 more
exaly +4 more sources
An Exposure-Response Perspective on the Clinical Dose of Pretomanid
Antimicrobial Agents and Chemotherapy, 2020 Pretomanid was approved by the U.S. FDA, via the limited population pathway for antibacterial and antifungal drugs, as part of a three-drug regimen with bedaquiline and linezolid for the treatment of extensively drug-resistant and treatment-intolerant or nonresponsive multidrug-resistant tuberculosis.
Jerry Nedelman +2 more
exaly +3 more sources
Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Pretomanid is a nitroimidazole antibiotic in late-phase clinical testing as a component of several novel antituberculosis (anti-TB) regimens. A population pharmacokinetic model for pretomanid was constructed using a Bayesian analysis of data from two phase 2 studies, PA-824-CL-007 and PA-824-CL-010, conducted with adult (median age ...
Michael A Lyons
exaly +5 more sources
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis [PDF]
New England Journal of Medicine, 2022 The bedaquiline-pretomanid-linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high. The appropriate dose of linezolid and duration of treatment with this agent to minimize toxic effects while maintaining efficacy against highly
Daniel Everitt +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Pretomanid: The latest USFDA-approved anti-tuberculosis drug
Indian Journal of Tuberculosis, 2021Pretomanid is a nitroimidazooxazine drug which inhibits synthesis of mycolic acid. This leads to defective cell wall formation, ultimately causing bacterial cell death. It is active against both replicating and non-replicating M. tuberculosis. Following promising result in a phase III trial, pretomanid was approved by United States Food and Drug ...
Uttiya Deb, Supreeti Biswas
exaly +3 more sources
Stable sugar and sugar-free suspensions of pretomanid
The International Journal of Tuberculosis and Lung Disease, 2022BACKGROUND: Pretomanid (PMD) tablets are indicated as part of a combination regimen for the treatment of adults with pulmonary extensively drug-resistant, treatment-intolerant or non-responsive multidrug-resistant TB. No commercial liquid formulation is currently available for patients unable to swallow these tablets.OBJECTIVE: To develop stable ...
R, Taneja +10 more
openaire +2 more sources
American Journal of Respiratory and Critical Care Medicine, 2023
Abstract Rationale Pretomanid is a new nitroimidazole with proven treatment-shortening efficacy in drug-resistant tuberculosis. Pretomanid–rifamycin–pyrazinamide combinations are potent in mice but have not been tested clinically. Rifampicin, but not rifabutin, reduces pretomanid exposures.
Kelly E Dooley +2 more
exaly +3 more sources
Abstract Rationale Pretomanid is a new nitroimidazole with proven treatment-shortening efficacy in drug-resistant tuberculosis. Pretomanid–rifamycin–pyrazinamide combinations are potent in mice but have not been tested clinically. Rifampicin, but not rifabutin, reduces pretomanid exposures.
Kelly E Dooley +2 more
exaly +3 more sources